Warning: The NCBI web site requires JavaScript to function. more...
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
Yuan R, Kay A, Berg WJ, Lebwohl D.
J Hematol Oncol. 2009 Oct 27;2:45. Review.
Related citations
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY, Grossman AB, Bukowski RM.
Adv Ther. 2010 Aug;27(8):495-511. Epub 2010 Jul 8. Review.
[mTOR inhibitors].
Oya M.
Nihon Rinsho. 2010 Jun;68(6):1067-71. Review. Japanese.
mTOR signaling and drug development in cancer.
Dancey J.
Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. Epub 2010 Mar 16. Review.
The mTOR pathway: a new target in cancer therapy.
Ciuffreda L, Di Sanza C, Incani UC, Milella M.
Curr Cancer Drug Targets. 2010 Aug;10(5):484-95. Review.
Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B, Ribrag V.
Leuk Lymphoma. 2009 Dec;50(12):1916-30. Review.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S, Bjelogrlic SK.
J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
[No authors listed]
Drugs R D. 2007;8(3):176-87. Review.
Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A, Figlin RA.
Cancer. 2009 Aug 15;115(16):3618-30. Review.
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA, Wilhelm S, Carter C, Kelley SL.
Semin Oncol. 2006 Aug;33(4):392-406. Review.
Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P.
BJU Int. 2009 Dec;104(11):1585-9. Review.
[Antitumoral effect of proliferation signal inhibitors].
Dumortier J.
Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S263-7. French.
Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S, Thompson JA.
Adv Ther. 2009 Jan;26(1):55-67. Epub 2009 Jan 26. Review.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Emerging treatment combinations: integrating therapy into clinical practice.
Wong ST.
Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S9-S14. Review.
Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK, Mughal TI, Rini BI.
Clin Genitourin Cancer. 2006 Sep;5(2):110-3. Review.
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.
Expert Opin Investig Drugs. 2009 Sep;18(9):1333-49. Review.
Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A, Sessa C.
Expert Opin Investig Drugs. 2011 Mar;20(3):381-94. Epub 2011 Feb 8. Review.
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K.
J Med Chem. 2010 Jan 14;53(1):452-9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on